Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Down 72.9% in June

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totaling 169,677 shares, a decrease of 72.9% from the May 31st total of 625,772 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily volume of 2,555,159 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vestor Capital LLC grew its holdings in Jupiter Neurosciences by 144,607.2% during the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the period. Geode Capital Management LLC grew its stake in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after buying an additional 28,826 shares in the last quarter. Yorkville Advisors Global LP acquired a new position in Jupiter Neurosciences during the fourth quarter worth approximately $135,000. Finally, Allen Capital Group LLC acquired a new position in Jupiter Neurosciences in the 4th quarter valued at about $31,000.

Jupiter Neurosciences Trading Up 19.6%

Shares of NASDAQ:JUNS opened at $0.28 on Friday. Jupiter Neurosciences has a 52 week low of $0.17 and a 52 week high of $3.33. The firm’s 50 day moving average is $0.30 and its two-hundred day moving average is $0.56. The firm has a market capitalization of $10.27 million, a P/E ratio of -1.05 and a beta of 1.71.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.23 million.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.